05.06 08:01 | dpa-AFX: *ASTRAZENECA COMPLETES ACQUISITION OF FUSION PHARMACEUTICALS |
05.06 07:17 | dpa-AFX: *HSBC RAISES ASTRAZENECA PRICE TARGET TO 14070 (12950) PENCE - 'BUY' |
05.06 07:17 | dpa-AFX: *HSBC HEBT ZIEL FÜR ASTRAZENECA AUF 14070 (12950) PENCE - 'BUY' |
04.06 11:08 | dpa-AFX: ANALYSE-FLASH: UBS belässt Astrazeneca auf 'Sell' - Ziel 11300 Pence |
04.06 11:08 | dpa-AFX: UBS belässt Astrazeneca auf 'Sell' - Ziel 11300 Pence |
03.06 12:37 | dpa-AFX: ANALYSE-FLASH: JPMorgan belässt Astrazeneca auf 'Overweight' - Ziel 13000 Pence |
03.06 12:37 | dpa-AFX: JPMorgan belässt Astrazeneca auf 'Overweight' - Ziel 13000 Pence |
03.06 08:24 | dpa-AFX: CHMP Recommends Approval Of AstraZeneca's Tagrisso Combo For EGFR-Mutated Advanced Lung Cancer |
03.06 08:11 | dpa-AFX: *ASTRAZENECA SAYS TAGRISSO + CHEMOTHERAPY RECOMMENDED FOR APPROVAL IN THE EU BY CHMP FOR PATIENTS WITH EGFR-MUTATED ADVANCED LUNG CANCER |
03.06 08:03 | dpa-AFX: *CHMP RECOMMENDS APPROVAL OF ASTRAZENECA'S TAGRISSO COMBINATION THERAPY FOR TREATMENT OF EGFR-MUTATED LUNG CANCER |
30.05 11:21 | dpa-AFX: Amgen's Bkemv Approved As First Interchangeable Biosimilar To Soliris |
30.05 08:05 | dpa-AFX: ANALYSE-FLASH: Goldman startet Astrazeneca mit 'Buy' - Ziel 15200 Pence |
30.05 08:05 | ANALYSE-FLASH: Goldman startet Astrazeneca mit 'Buy' - Ziel 15200 Pence |
30.05 07:06 | dpa-AFX: ANALYSE-FLASH: Goldman startet Astrazeneca mit 'Buy' - Ziel 15200 Pence |
30.05 07:05 | dpa-AFX: Goldman startet Astrazeneca mit 'Buy' - Ziel 15200 Pence |
30.05 06:57 | dpa-AFX: *GOLDMAN STARTET ASTRAZENECA MIT 'BUY' - ZIEL 15200 PENCE |
30.05 06:57 | dpa-AFX: *GOLDMAN STARTS ASTRAZENECA WITH 'BUY' - PRICE TARGET 15200 PENCE |
28.05 09:31 | dpa-AFX: JPMorgan belässt Astrazeneca auf 'Overweight' - Ziel 13000 Pence |
27.05 08:34 | dpa-AFX: AZN:Datopotamab Deruxtecan Shows Favorable Survival Results, Falls Short Of Statistical Significance |
22.05 13:04 | dpa-AFX: *ASTRAZENECA ADVANCES ITS AMBITION TO REDEFINE CANCER CARE WITH NEW DATA ACROSS ITS PORTFOLIO AND PIPELINE AT ASCO |
|